She notes that "when people [generally] lose even a small amount of weight and improve their metabolic health, their risk of depression and anxiety goes down." This pattern existed before what she calls the "Ozempic revolution." In 2024, following an uptick in reports of suicidal thoughts and behaviors associated with GLP-1 use, the U.S
Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes and metabolic dysfunction-associated steatotic liver disease
Typically, you must stop GLP-1 agonists 1 to 2 weeks before elective surgery to reduce the risk of aspiration under anesthesia
Current evidence regarding the impact of GLP-1 receptor agonists on ophthalmic diseases remains inconsistent. Retinopathy remains the dominant concern Much of the ophthalmic attention surrounding GLP-1 therapies traces back to DR
Pick a day when you can take it easy if needed